Iridex Reports Second Quarter 2023 Financial Results
- None.
- 7% year-over-year decrease in total revenue
- 9% decrease in retina product revenue
- $2.8 million net loss for the quarter
- Reduction in royalty revenue
- $1.2 million cash use in the second quarter
MOUNTAIN VIEW, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today reported financial results for the second quarter ended July 1, 2023.
Second Quarter 2023 Highlights
- Generated total revenue of
$12.9 million , a decrease of7% year-over-year - Cyclo G6® product family revenue of
$3.7 million increased5% year-over-year- 41 Cyclo G6 Glaucoma Laser Systems sold, compared to 48 in the prior year period
- 15,500 Cyclo G6 probes sold representing a
9% revenue increase and4% unit increase year-over-year
- Retina product revenue was
$6.9 million , a decrease of9% year-over-year - 16 posters presented at the World Glaucoma Congress demonstrate rising clinical interest in MicroPulse® Transcleral Laser Therapy and the Cyclo G6 product family
- Cash and cash equivalents totaled approximately
$9.8 million as of July 1, 2023
“Our second quarter results reflect continued modest glaucoma business growth offset by declines in surgical and medical retina systems and lower royalty revenue. Softer capital equipment shipments reflected elongated purchasing cycles that led to the decline in the retina business in the quarter, but we expect capital demand to stabilize during the second half of the year,” said David Bruce, Iridex President and CEO. “While our initiatives to accelerate G6 probe utilization are taking longer to gain traction, we remain confident we are building the foundation for long-term adoption in the large population of moderate stage glaucoma patients. We are making progress with Sweep Management software system upgrades, increasing awareness of the effective dosing guidance that enables consistent clinical outcomes, and advancing toward a planned large multicenter prospective trial to further validate the safety and effectiveness of MPTLT. We believe these initiatives coupled with increasing positive proof of efficacy and safety, such as those presented at this year’s World Glaucoma Congress, will increase our future growth rate.”
Second Quarter 2023 Financial Results
Revenue for the three months ended July 1, 2023 was
Gross profit for the second quarter of 2023 was
Operating expenses for the second quarter of 2023 decreased to
Net loss for the second quarter of 2023 was
Cash and cash equivalents totaled
Guidance for Full Year 2023
With lower than expected probe unit sales growth and capital equipment softness in the first half of the year, the Company is updating its full year 2023 expectations as follows: Cyclo G6 probe sales of 61,000 to 63,000 units representing approximately
Webcast and Conference Call Information
Iridex’s management team will host a conference call today beginning at 2:00 p.m. PT / 5:00 p.m. ET. Investors interested in listening to the conference call may do so by accessing the live and recorded webcast on the “Event Calendar” page of the “Investors” section of the Company’s website at www.iridex.com.
About Iridex
Iridex Corporation is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. The Company’s proprietary MicroPulse® technology delivers a differentiated treatment that provides safe, effective, and proven treatment for targeted sight-threatening eye conditions. Iridex’s current product line is used for the treatment of glaucoma and diabetic macular edema (DME) and other retinal diseases. Iridex products are sold in the United States through a direct sales force and internationally primarily through a network of independent distributors into more than 100 countries. For further information, visit the Iridex website at www.iridex.com.
Safe Harbor Statement
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Act of 1934, as amended, including those statements concerning clinical expectations and commercial momentum, market adoption and expansion, demand for and utilization of the Company's products, financial guidance and results and expected sales volumes. These statements are not guarantees of future performance and actual results may differ materially from those described in these forward-looking statements as a result of a number of factors. Please see a detailed description of these and other risks contained in our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 10, 2023. Forward-looking statements contained in this announcement are made as of this date and will not be updated.
Investor Relations Contact
Philip Taylor
Gilmartin Group
investors@iridex.com
IRIDEX Corporation Condensed Consolidated Statements of Operations (In thousands, except per share data) (unaudited) | ||||||||||||||||||
Three Months Ended | Six Months Ended | |||||||||||||||||
July 1, | July 2, | July 1, | July 2, | |||||||||||||||
2023 | 2022 | 2023 | 2022 | |||||||||||||||
Total revenues | $ | 12,855 | $ | 13,755 | $ | 26,561 | $ | 27,142 | ||||||||||
Cost of revenues | 7,492 | 7,488 | 15,260 | 14,898 | ||||||||||||||
Gross profit | 5,363 | 6,267 | 11,301 | 12,244 | ||||||||||||||
Operating expenses: | ||||||||||||||||||
Research and development | 1,845 | 1,922 | 3,594 | 4,038 | ||||||||||||||
Sales and marketing | 4,264 | 4,607 | 8,547 | 8,907 | ||||||||||||||
General and administrative | 2,148 | 1,898 | 4,398 | 3,736 | ||||||||||||||
Total operating expenses | 8,257 | 8,427 | 16,539 | 16,681 | ||||||||||||||
Loss from operations | (2,894 | ) | (2,160 | ) | (5,238 | ) | (4,437 | ) | ||||||||||
Other income (expense), net | 138 | (64 | ) | 404 | (158 | ) | ||||||||||||
Loss from operations before provision for income taxes | (2,756 | ) | (2,224 | ) | (4,834 | ) | (4,595 | ) | ||||||||||
Provision for income taxes | 10 | 17 | 22 | 37 | ||||||||||||||
Net loss | $ | (2,766 | ) | $ | (2,241 | ) | $ | (4,856 | ) | $ | (4,632 | ) | ||||||
Net loss per share: | ||||||||||||||||||
Basic | $ | (0.17 | ) | $ | (0.14 | ) | $ | (0.30 | ) | $ | (0.29 | ) | ||||||
Diluted | $ | (0.17 | ) | $ | (0.14 | ) | $ | (0.30 | ) | $ | (0.29 | ) | ||||||
Weighted average shares used in computing net loss per share: | ||||||||||||||||||
Basic | 16,036 | 15,894 | 16,018 | 15,888 | ||||||||||||||
Diluted | 16,036 | 15,894 | 16,018 | 15,888 |
IRIDEX Corporation Condensed Consolidated Balance Sheets (In thousands and unaudited) | |||||||||
July 1, | December 31, | ||||||||
2023 | 2022 | ||||||||
Assets | |||||||||
Current assets: | |||||||||
Cash and cash equivalents | $ | 9,821 | $ | 13,922 | |||||
Accounts receivable, net | 8,799 | 9,768 | |||||||
Inventories | 11,129 | 10,608 | |||||||
Prepaid expenses and other current assets | 1,216 | 1,468 | |||||||
Total current assets | 30,965 | 35,766 | |||||||
Property and equipment, net | 397 | 462 | |||||||
Intangible assets, net | 1,810 | 1,977 | |||||||
Goodwill | 965 | 965 | |||||||
Operating lease right-of-use assets, net | 1,138 | 1,665 | |||||||
Other long-term assets | 1,664 | 1,455 | |||||||
Total assets | $ | 36,939 | $ | 42,290 | |||||
Liabilities and Stockholders’ Equity | |||||||||
Current liabilities: | |||||||||
Accounts payable | $ | 4,278 | $ | 3,873 | |||||
Accrued compensation | 2,163 | 2,448 | |||||||
Accrued expenses | 1,395 | 1,548 | |||||||
Other current liabilities | 825 | 968 | |||||||
Accrued warranty | 215 | 168 | |||||||
Deferred revenue | 2,310 | 2,411 | |||||||
Operating lease liabilities | 1,049 | 1,037 | |||||||
Total current liabilities | 12,235 | 12,453 | |||||||
Long-term liabilities: | |||||||||
Accrued warranty | 138 | 106 | |||||||
Deferred revenue | 10,881 | 11,742 | |||||||
Operating lease liabilities | 210 | 732 | |||||||
Other long-term liabilities | 25 | 26 | |||||||
Total liabilities | 23,489 | 25,059 | |||||||
Stockholders' equity: | |||||||||
Common stock | 171 | 169 | |||||||
Additional paid-in capital | 87,647 | 86,802 | |||||||
Accumulated other comprehensive loss | (40 | ) | (24 | ) | |||||
Accumulated deficit | (74,328 | ) | (69,716 | ) | |||||
Total stockholders' equity | 13,450 | 17,231 | |||||||
Total liabilities and stockholders' equity | $ | 36,939 | $ | 42,290 |
FAQ
What is the ticker symbol for Iridex Corporation?
What was the total revenue for Iridex Corporation in the second quarter of 2023?
What was the percentage change in Cyclo G6 product family revenue compared to the prior year period?
What was the net loss for Iridex Corporation in the second quarter of 2023?